Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer.

ABSTRACT: De novo lipogenesis (DNL) is now considered as a hallmark of cancer. The overexpression of key enzymes of DNL is characteristic of both primary and advanced disease and may play an important role in resistance to therapies. Here, we showed that DNL is highly enhanced in castrate resistant prostate cancer (CRPC) cells compared to hormone sensitive and enzalutamide resistant cells. This observation suggests that this pathway plays an important role in the initiation of aggressive prostate cancer and in the development of enzalutamide resistance. Importantly, here we show that both prostate cancer cells sensitive and resistant to enzalutamide are dependent on DNL to proliferate. We next combined enzalutamide with an inhibitor of Stearoyl CoA Desaturase 1 (SCD1), an important enzyme in DNL, an

SUBMITTER: Lounis MA 

PROVIDER: S-EPMC7698241 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature